Boston Scientific (BSX) Aktienübersicht
Die Boston Scientific Corporation entwickelt, produziert und vertreibt weltweit medizinische Geräte für den Einsatz in verschiedenen interventionellen medizinischen Fachgebieten. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 1/6 |
| Vergangene Leistung | 5/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
BSX unsere Risikoprüfungen bestanden.
BSX Community Fair Values
Create NarrativeSee what 145 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$98.9
FV
54.2% unterbewertet intrinsischer Abschlag9.80%
Revenue growth p.a.
543
users have viewed this narrative1users have liked this narrative
1users have commented on this narrative
19users have followed this narrative
Boston Scientific Corporation Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$45.30 |
| 52-Wochen-Hoch | US$109.50 |
| 52-Wochen-Tief | US$42.25 |
| Beta | 0.58 |
| 1 Monat Veränderung | -6.69% |
| 3 Monate Veränderung | -27.59% |
| 1 Jahr Veränderung | -55.77% |
| 3 Jahre Veränderung | -13.63% |
| 5 Jahre Veränderung | 5.20% |
| Veränderung seit IPO | 958.10% |
Aktuelle Nachrichten und Updates
Seeking Alpha • Jul 06
Boston Scientific: The Time Has Come To Catch This Falling Knife
Summary Relative to its all-time high of $109.50 reached in September 2025, Boston Scientific Corporation's share price has declined by almost 60% to trade at around $45.00 per share. To put my money where my mouth is, I purchased my last shares on June 30th at an average price of $42.83. My overall purchase price now stands at $45.52. As part of its Q1-26 earnings, Boston Scientific announced a significant outlook revision, reducing its organic growth guidance for fiscal 2026 to a range between 6.5% and 8.0%. With a $4.0 billion free cash flow guidance, BSX currently trades at an FCF yield of approximately 6.0%, which is one of the highest in the company's history. Given where the stock is trading, I am encouraged by the $2.0 billion accelerated share repurchase program announced last May. It is quite unusual for Boston Scientific to aggressively repurchase its own shares, as we have to go all the way back to fiscal 2020 to find the last share repurchases. Read the full article on Seeking Alpha
Narrativ-Update • Jun 30
BSX: Clinical Pipeline Strength Will Offset Watchman Reset And Sector Headwinds
The analyst price target for Boston Scientific has been reduced by $2.10, from $77.10 to $75.00, as analysts factor in slower Watchman growth, lower utilization trends, and more conservative long term revenue and margin assumptions across the medtech sector. Analyst Commentary Recent research on Boston Scientific points to a clear split between optimism on the broader business and caution around Watchman and utilization trends.Analyseartikel • Jun 19
Boston Scientific (BSX) Stock Could Be 54.2% Undervalued After Soft 2026 Guidance
Boston Scientific (BSX) shares have come under pressure after the company issued 2026 guidance that fell short of market expectations, with investors focusing on slowing revenue growth in its electrophysiology segment. See our latest analysis for Boston Scientific. At a share price of $45.29, Boston Scientific has seen pressure build, with the 30 day share price return down 20.28% and the year to date share price return down 52.18%. The 1 year total shareholder return is down 55.32%, pointing...Recent updates
Seeking Alpha • Jul 06
Boston Scientific: The Time Has Come To Catch This Falling Knife
Summary Relative to its all-time high of $109.50 reached in September 2025, Boston Scientific Corporation's share price has declined by almost 60% to trade at around $45.00 per share. To put my money where my mouth is, I purchased my last shares on June 30th at an average price of $42.83. My overall purchase price now stands at $45.52. As part of its Q1-26 earnings, Boston Scientific announced a significant outlook revision, reducing its organic growth guidance for fiscal 2026 to a range between 6.5% and 8.0%. With a $4.0 billion free cash flow guidance, BSX currently trades at an FCF yield of approximately 6.0%, which is one of the highest in the company's history. Given where the stock is trading, I am encouraged by the $2.0 billion accelerated share repurchase program announced last May. It is quite unusual for Boston Scientific to aggressively repurchase its own shares, as we have to go all the way back to fiscal 2020 to find the last share repurchases. Read the full article on Seeking AlphaNarrativ-Update • Jun 30
BSX: Clinical Pipeline Strength Will Offset Watchman Reset And Sector Headwinds
The analyst price target for Boston Scientific has been reduced by $2.10, from $77.10 to $75.00, as analysts factor in slower Watchman growth, lower utilization trends, and more conservative long term revenue and margin assumptions across the medtech sector. Analyst Commentary Recent research on Boston Scientific points to a clear split between optimism on the broader business and caution around Watchman and utilization trends.Analyseartikel • Jun 19
Boston Scientific (BSX) Stock Could Be 54.2% Undervalued After Soft 2026 Guidance
Boston Scientific (BSX) shares have come under pressure after the company issued 2026 guidance that fell short of market expectations, with investors focusing on slowing revenue growth in its electrophysiology segment. See our latest analysis for Boston Scientific. At a share price of $45.29, Boston Scientific has seen pressure build, with the 30 day share price return down 20.28% and the year to date share price return down 52.18%. The 1 year total shareholder return is down 55.32%, pointing...Narrativ-Update • Jun 16
BSX: Clinical Pipeline And Share Repurchases Will Support Rebased Expectations
Boston Scientific's fair value estimate has been trimmed from $79.40 to $77.10, as analysts lower price targets across the sector and factor in slower Watchman growth, a more cautious utilization backdrop, and slightly reduced long term revenue and margin assumptions. Analyst Commentary Recent Street research on Boston Scientific clusters around a similar theme, with most firms trimming price targets and revisiting assumptions on growth, margins, and valuation after the latest Watchman commentary and a softer utilization backdrop.Narrativ-Update • Jun 01
BSX: Clinical Pipeline And Capital Deployment Will Support Rebased Expectations
Boston Scientific's updated analyst price target has shifted lower by about $5.80 to $79.40, as analysts factor in slower growth expectations for the Watchman franchise and slightly softer forecasts for revenue growth, profit margins, and future P/E. Analyst Commentary Recent Street research around Boston Scientific reflects a mix of optimism and caution, with most firms trimming price targets to align with updated expectations for the Watchman franchise, organic sales growth, and sector-wide medtech valuations.Narrativ-Update • May 08
BSX: Clinical Wins And Pipeline Strength Will Support Rebased Expectations
Analysts have trimmed the Boston Scientific fair value estimate from $95.75 to $85.19 after a series of price target cuts across the Street. The change reflects updated assumptions for slower revenue growth, slightly higher profit margins, and a lower forward P/E multiple.
Neues Narrativ • Apr 24
Minimally Invasive Therapies And Atrial Fibrillation Treatments Will Support Steady Prospects Ahead
Catalysts About Boston Scientific Boston Scientific is a global medical technology company that develops and sells devices used in cardiology, electrophysiology, urology, endoscopy, neuromodulation and other interventional procedures. What are the underlying business or industry changes driving this perspective?Narrativ-Update • Apr 22
BSX: Clinical Trial Wins Will Offset Reset Expectations And Battery Concerns
Analysts have trimmed the fair value estimate for Boston Scientific to $95.75 from $100.31, reflecting a series of lower Street price targets and slightly more conservative assumptions on growth, profitability, and future P/E multiples. Analyst Commentary Recent research coverage on Boston Scientific has centered on a broad reset of expectations, with many firms revising price targets and, in some cases, ratings.
Neues Narrativ • Apr 08
Pulsed Field Ablation And Minimally Invasive Therapies Will Reshape Long Term Procedure Volumes
Catalysts About Boston Scientific Boston Scientific develops and sells medical devices across cardiovascular, electrophysiology, neuromodulation, endoscopy, urology and related therapeutic areas worldwide. What are the underlying business or industry changes driving this perspective?Narrativ-Update • Apr 07
BSX: Clinical Wins And 2026 Outlook Will Outweigh Pacemaker Battery Concerns
Boston Scientific's analyst fair value estimate shifts modestly lower from $102.00 to about $100.31, as analysts recalibrate price targets across the group following recent clinical data, rating changes, and updated sector models. Analyst Commentary Recent Street research around Boston Scientific clusters around a common theme, with many firms trimming price targets and a smaller group highlighting potential upside tied to execution and clinical progress.Narrativ-Update • Mar 24
BSX: Reorganized Segments And 2026 Outlook Should Offset Recent Pacemaker Headlines
Analysts have trimmed the Boston Scientific fair value estimate by about $2 to $102, reflecting a series of reduced Street price targets that incorporate slightly lower revenue growth assumptions, a marginally higher discount rate, and modest tweaks to long term margin and future P/E expectations. Analyst Commentary Street research on Boston Scientific has been active, with most recent moves clustered around price target resets and list changes.Narrativ-Update • Mar 08
BSX: Reorganized Segments And 2026 Outlook Should Support Sentiment Rebound
Analysts have trimmed their blended price target on Boston Scientific by about $0.50 to roughly $104.25. This reflects updated models following the company reorganization and recent management commentary.Narrativ-Update • Feb 22
BSX: Organizational Changes Should Support Rebound As 2026 Patterns Normalize
Analysts have trimmed their average price target on Boston Scientific to $104.75 from $108.66, citing updated models that factor in recent organizational changes and management commentary following the latest earnings call. Analyst Commentary Across Wall Street, most research updates on Boston Scientific center on revised models and valuation resets rather than outright changes in long term views.Narrativ-Update • Feb 06
BSX: Execution Outperformance Should Drive Rebound As 2026 Patterns Normalize
The analyst price target for Boston Scientific has been reduced by about $17 to align with updated Street research. This reflects slightly lower revenue growth assumptions, a modestly higher discount rate, and a lower future P/E multiple, while profit margin expectations remain steady.
Neues Narrativ • Jan 25
BSX after Penumbra ?
The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons: * Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we've seen in the recent price dips.Narrativ-Update • Jan 10
BSX: Shares Should Rise On Execution Outperformance And 2026 Normalization Potential
Analysts have trimmed their Boston Scientific fair value estimate slightly to about $125.45 from $125.86, reflecting fine tuning of discount rate, revenue growth, profit margin and future P/E assumptions in light of recent price target resets and largely supportive research commentary across the MedTech sector. Analyst Commentary Recent Street research on Boston Scientific reflects generally constructive views on execution and growth, with some recalibration of targets as models are updated after quarterly results and sector wide resets.Narrativ-Update • Dec 25
BSX: Shares Will Rise On Execution Outperformance And Three Year Growth Plan
Analysts have nudged their fair value estimate for Boston Scientific slightly lower to approximately $126 per share, even as multiple firms have lifted price targets into the $124 to $136 range, citing sustained double digit revenue growth, a robust pipeline, and potential upside from recent acquisitions and Q3 outperformance. Analyst Commentary Bullish analysts largely frame Boston Scientific as a durable double digit grower with room for further multiple expansion, pointing to recent Q3 upside, raised long term targets, and a steady cadence of accretive deals as support for valuations near or above current levels.Narrativ-Update • Dec 11
BSX: Shares Will Rise On Earnings Strength And Multi Year Execution Momentum
Analysts nudged their average price target for Boston Scientific modestly higher, toward the low to mid $130 range, citing the company’s Q3 beat, accelerating Watchman adoption, confidence in multi year guidance, and a robust growth pipeline supported by strategic acquisitions like Nalu, despite some cautions on valuation and longer term growth moderation. Analyst Commentary Analyst reaction to Boston Scientific's latest results and strategic updates has been predominantly positive, with several firms raising price targets and reiterating favorable ratings, while a minority voice has started to flag valuation and medium term growth risks.Narrativ-Update • Nov 27
BSX: Shares Will Advance On Earnings Strength And Merger Execution Momentum
Boston Scientific's analyst price targets have been raised by several dollars, with most now clustered around $130 per share. Analysts highlight robust quarterly results, accelerating growth segments, and confidence in the company’s long-range outlook.Narrativ-Update • Nov 07
BSX: Shares Will See Momentum From Recent Acquisition And Execution Confidence
Boston Scientific's analyst price target has been increased modestly, with the consensus now reflecting a higher fair value in addition to ongoing confidence in robust growth prospects and recent business performance, as analysts cite solid quarterly results, improving guidance, and successful strategic acquisitions. Analyst Commentary Recent analyst research on Boston Scientific highlights both optimistic and cautious perspectives regarding the company's valuation, strategic moves, and long-term growth outlook.Narrativ-Update • Oct 24
Future Growth Plans And Acquisitions Will Drive Broader Market Expansion
Analysts have raised their price target for Boston Scientific to approximately $126, up from $124.53. They cite renewed confidence in the company’s earnings outlook, along with improvements in profit margin and future growth expectations, following strong quarterly performance.Analyseartikel • Jul 21
Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Seeking Alpha • Mar 18
Boston Scientific: Bright Future, Rather Pricey
Summary A diversified portfolio, strategic acquisitions, and aggressive R&D have driven Boston Scientific's recent revenue and EPS growth, outpacing peers like Abbott and Medtronic. Consequently, BSX stock is trading at a significant premium, reflecting high investor optimism. Intense competition along with regulatory and safety concerns also remain key challenges. While Boston's fundamentals suggest that double-digit earnings growth can be sustained, there may be little margin for error at the current stock price. I recommend a Hold at ~$97. Read the full article on Seeking AlphaAktionärsrenditen
| BSX | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 6.1% | 5.7% | -0.7% |
| 1Y | -55.8% | -17.8% | 20.3% |
Rendite im Vergleich zur Industrie: BSX unter dem Niveau der Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -17.8% erzielte.
Rendite vs. Markt: BSX hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 20.3 erzielte.
Preisvolatilität
| BSX volatility | |
|---|---|
| BSX Average Weekly Movement | 6.4% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: BSX hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: BSXDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1979 | 59,000 | Mike Mahoney | www.bostonscientific.com |
Die Boston Scientific Corporation entwickelt, produziert und vertreibt weltweit medizinische Geräte für den Einsatz in verschiedenen interventionellen medizinischen Fachgebieten. Das Unternehmen ist in zwei Segmenten tätig, MedSurg und Cardiovascular. Es bietet Geräte zur Diagnose und Behandlung einer Reihe von gastrointestinalen Erkrankungen an, wie z.B.
Boston Scientific Corporation's Grundlagenzusammenfassung
| BSX grundlegende Statistiken | |
|---|---|
| Marktanteil | US$66.29b |
| Gewinn(TTM) | US$3.57b |
| Umsatz(TTM) | US$20.61b |
18.9x
Kurs-Gewinn-Verhältnis 3.3x
Kurs-Umsatz-VerhältnisIst BSX zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| BSX Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$20.61b |
| Kosten der Einnahmen | US$6.40b |
| Bruttogewinn | US$14.21b |
| Sonstige Ausgaben | US$10.65b |
| Gewinn | US$3.57b |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
Jul 29, 2026
| Gewinn per Aktie (EPS) | 2.40 |
| Bruttomarge | 68.94% |
| Nettogewinnspanne | 17.29% |
| Schulden/Eigenkapital-Verhältnis | 41.8% |
Wie hat sich BSX auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/07 06:31 |
| Aktienkurs zum Tagesende | 2026/07/07 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Boston Scientific Corporation wird von 58 Analysten beobachtet. 29 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jasper Hellweg | Argus Research Company |
| David Rescott | Baird |
| null null | Baird |